about
Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemiaThe BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cellsAntidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.The BAFF/APRIL system in SLE pathogenesis.Roles of ligands from the TNF superfamily in B cell development, function, and regulation.What has the Young Physician Leaders Programme achieved?Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept.The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death.BAFF-driven autoimmunity requires CD19 expression.Seasonal influenza vaccine coverage of patients on biotherapy for inflammatory joint disease in Normandy, France.Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosusAnalysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosusAnalysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosisAnalysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosisAnalysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosusInfluenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDsTumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre studyEffect of storage duration on cytokine stability in human serum and plasmaEffect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritisAssociations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
P50
Q33910990-40C3897B-E2DB-411F-B869-05ACE7AF62AFQ36165173-128BFA31-8509-4B28-8A3C-D7DEADEFEB00Q38062273-29CFB085-CE83-4889-AD95-3C18CAEEBC8BQ38194895-F1F25F00-D55A-4DE9-A356-3618FE3002DAQ38226385-2A53DCA7-4FAD-4F82-A7A3-DC2A5CF3B74BQ43519143-9B03D475-536A-4970-AAC3-D8B597E20F69Q45193661-A222FCB8-BCE8-4A68-972C-014DF27405BAQ46193158-D6C03315-E391-47D8-A4CC-BBB20CF7FAECQ52935473-C429D531-9399-44FD-9E32-C8EA986442E0Q53321602-99851FD6-81B2-47C4-8C30-3F699D5F0CCEQ55401570-FA2190DC-4A8B-4C77-9482-97578C0A4DDCQ57291047-545C68ED-F74D-4324-B21F-5FBB0B418EE5Q58588970-48E441C7-EC99-4621-BA57-22EEB7DE5B4AQ59791080-A60C475E-2D5A-4B28-A59A-BA644C0C4498Q64069408-4C0DEBF7-41CB-4A88-B610-7D8C12D01AF6Q64099842-53A0D380-4D97-4574-A56E-507EB3B89084Q85624219-CBBC3B71-BB27-43EA-82E5-688D97CA9287Q86717897-93E862D7-D2C1-4621-B8B5-3A9EF5D1A71AQ89128813-9929F8C1-20C6-40B5-86BE-CB38A93C680BQ89162034-7A649337-7B78-4481-B26D-A2D6FB62B979Q96431213-0139AC14-F9EE-492D-9A12-C3FB625B5D04
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabien B Vincent
@ast
Fabien B Vincent
@en
Fabien B Vincent
@es
Fabien B Vincent
@nl
type
label
Fabien B Vincent
@ast
Fabien B Vincent
@en
Fabien B Vincent
@es
Fabien B Vincent
@nl
prefLabel
Fabien B Vincent
@ast
Fabien B Vincent
@en
Fabien B Vincent
@es
Fabien B Vincent
@nl
P106
P1153
24777556100
P31
P496
0000-0001-7220-0800